Day: April 25, 2025

WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. Eastern Time on June 23, 2025. Stockholders of record as of April 30, 2025, will be asked to vote on the re-election of two incumbent director nominees, and the ratification of the Company’s independent registered public accounting firm. Tevogen Bio encourages all stockholders of record as of April 30, 2025, to participate in this year’s vote. Proxy materials, including detailed instructions for voting, will be distributed or made available in accordance with Securities and Exchange Commission (“SEC”) regulations to stockholders of record as of April 30, 2025. If you are a stockholder...

Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor types Data to be presented at 2025 AACR Annual MeetingSAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian,...

Approximately 20,000 homes to be powered with clean, renewable energy from DTE’s Pine River Solar Park when fully online this spring Detroit, April 25, 2025 (GLOBE NEWSWIRE) — DTE Energy (NYSE:DTE), Michigan’s largest producer of and investor in renewable energy, announced that construction has been completed at Pine River Solar Park during a ribbon-cutting ceremony at the site today. Located in mid-Michigan’s Pine River Township, the 80-megawatt renewable energy development has more than 180,000 solar panels and will generate enough clean energy to power nearly 20,000 homes.  Pine River Solar is the second of DTE’s three new solar parks to be connected to the electric grid in 2025, and the company has five additional parks under construction. These projects are reflective of DTE’s customers’ demand for clean energy and are...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, IL. “The breadth of data shared at AACR highlights...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company’s lead investigational therapeutic cancer vaccine which targets cells expressing IDO1 and PD-L1, compared to conventional checkpoint inhibitors and a second shares promising...

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of BDC-3042 REDWOOD CITY, Calif., April 25, 2025 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced results from its Phase 1 dose-escalation clinical study of BDC-3042 at the American Association for Cancer Research...

Nurix’s lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour   BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models  SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced multiple preclinical presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting supporting several programs, each with different drug targets...

Corporate Rebranding Marks New Era of Engineering Excellence and Sustainable Solutions SINGAPORE, April 25, 2025 (GLOBE NEWSWIRE) — SAG Holdings Limited today announced that it has changed its name to INNEOVA Holdings Limited (“INNEOVA Holdings” or the “Company”), (Nasdaq: SAG; new trading symbol INEO). INNEOVA Holdings is a Singapore-based provider of high-quality Original Equipment Manufacturer (“OEM”), third-party branded and in-house branded replacement parts for motor vehicles and non-vehicle combustion engines. The name change is part of the Company’s comprehensive rebranding, and was approved by its shareholders on March 31, 2025. The Company trades on the the Nasdaq Capital Market and is changing its symbol from SAG to INEO, effective as of April 28, 2025 The Company is adopting the INNEOVA brand globally, reflecting its...